Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics : Market Research Report

Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics

Published: Jul. 1, 2009 - 589 Pages

Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in asset purchase dealmaking: 2.1. Introduction; 2.2. Types of asset purchased; 2.3. Reasons for entering into asset purchase partnering deals; 2.4 The emergence of royalty asset purchase deals; 2.5. The role of IP auction houses in asset purchase deals; 2.6. The future of asset purchase agreements
Chapter 3 - Overview of asset purchase deal structure: 3.1. Introduction; 3.2. Anatomy of an asset purchase deal; 3.3. Example asset purchase agreements; 3.4. Anatomy of a royalty asset purchase agreement; 3.5. Example royalty asset purchase agreements
Chapter 4 - Leading product and asset purchase deals: 4.1. Introduction; 4.2. Top business asset deals by value; 4.3. Top product asset deals by value; 4.4. Top royalty asset deals by value; 4.5. Bigpharma asset purchase deal activity
Chapter 5 - Bigpharma product and asset purchase agreements: 5.1. Introduction; 5.2. How to use product and asset purchase agreements; 5.3. Company product and asset purchasing agreement listings
Chapter 6 - Product and asset purchase partnering agreement directory 2000-2008: 6.1. Introduction; 6.2. Company A-Z; 6.3. By asset type; 6.4. By therapy area

Appendix 1 - Product and asset partnering references
Appendix 2 - Resources
Appendix 3 - Deal type definitions
Appendix 4 - Example product asset purchase contract: About CurrentPartnering
Table of figures: Figure 1: Definition of assets purchased; Figure 2: Trends in asset purchase deal announcements, 2000-2008; Figure 3: Leading royalty asset investors; Figure 4: Recent royalty asset purchase agreement; Figure 5: Leading IP auction companies; Figure 6: Components of the asset purchase deal structure; Figure 7: Components of the royalty asset purchase deal structure; Figure 8: Top business asset deals by value since 2003; Figure 9: Top product asset deals since 2003; Figure 10: Top royalty asset deals since 2003; Figure 11: Bigpharma - top 50 - asset purchase deals since 2003; Figure 12: Online partnering resources; Figure 13: Deal type definitions; Figure 14: Sample asset purchase agreement: Epoch Biosciences - Nanogen - DRI Capital - Sept 2006 - Asset purchase agreement for royalty interest in minor groove binder technology

Abstract

The Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics, 2nd edition report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the worlds leading biopharma companies.

This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of manufacturing and supply agreements from 2003 to early 2009.

The report provides a detailed understanding and analysis of how and why companies enter manufacturing and supply deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 1000 links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of manufacturing and supply dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in manufacturing and supply as well as a discussion on the merits of each type of deal.

Chapters 3 and 4 provide an overview of the structure of manufacturing and supply deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure manufacturing/supply deals and multicomponent deals where manufacturing/supply forms a part.

Chapters 5 and 6 provide a review of the leading manufacturing/supply deals since 2000, respectively. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 7 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of manufacturing and supply contract documents available in the public domain. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapters 8 and 9 provide a comprehensive listing of all manufacturing and supply agreement contracts since 2003 available in the public domain, respectively. Each chapter is organized by A-Z, stage of development at signing, and therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in manufacturing and supply dealmaking since 2000.

In conclusion, this report provides everything a prospective dealmaker needs to know about manufacturing and supply as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

Key benefits Manufacturing and Supply Agreements in Biopharma provides the reader with the following key benefits:

In-depth understanding of manufacturing and supply deal trends since 2000
Analysis of the structure of manufacturing and supply agreements with numerous real life case studies
Comprehensive access to over 1000 actual manufacturing and supply contracts entered into by the world’s biopharma companies
Detailed access to actual manufacturing and supply contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a manufacturing and supply agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics

Table of Contents

Abstract